Vaxxinity, Inc. announced that Nature Medicine has published exploratory data from the Company?s Phase 1 clinical trial of UB-312 in patients with Parkinson's disease (PD). The successful trial included measures of clinical efficacy, as well as exploratory research funded by The Michael J. Fox Foundation (MJFF) assessing target engagement in collaboration with the Mayo Clinic and UTHealth Houston. UB-312-induced antibodies significantly decreased levels of aggregated a-synuclein (aSyn), a key pathology in PD and other synucleinopathies, as measured by a semi-quantitative seed amplification assay (SAA).

This suggests that UB-312 can help to eliminate the buildup of harmful, toxic forms of the protein aSyn in the brain. Patients with detectable UB-312-induced antibodies in cerebrospinal fluid (CSF) exhibited significant improvement in motor experiences of daily living as measured by the MDS-UPDRS Part II, a commonly accepted clinical scale. This marks a potentially significant milestone in the pursuit of innovative PD care.

The Phase 1 successfully met its primary outcome measures, demonstrating UB-312 was generally well-tolerated and induced anti-aSyn antibody responses in healthy volunteers and PD patients. 12 out of 13 PD patients who completed dosing developed anti-aSyn antibodies.